Skip to main content
. Author manuscript; available in PMC: 2021 Jan 14.
Published in final edited form as: Ann Surg Oncol. 2020 May 20;27(11):4475–4485. doi: 10.1245/s10434-020-08608-1

Fig. 1.

Fig. 1

Patients with ER negative status and more advanced pathological AJCC Stage were more common in Grade 3 BCs in the all cohorts. Also, Grade 3 BCs were more prevalent in Basal, HER2, and Luminal B subtypes, compared to Luminal A subtype on PAM50 classification in the all cohorts (all p<0.001). Furthermore, Grade 3 BCs demonstrated higher gene expression of MKI67 (all p<0.001).

ER, estrogen receptor; AJCC, American Joint Committee for Cancer